This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Samuel Baron, MD; Stephen K. Tyring, MD, PhD
University of Texas Medical Branch Galveston

JAMA. 1992;267(4):509.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We agree with Drs Cribb, Renton, and Armstrong's point that interferon may suppress hepatic cytochrome P-450—dependent drug metabolism and that this interaction may increase the possibility of adverse drug events in patients treated with interferon.

Since submission of our review, another possible adverse result of interferon therapy has also been reported: the development of autoimmunity (eg, antinuclear antibodies and autoimmune thyroid disease).¹ Therefore, patients receiving interferon therapy should be monitored for development of autoantibodies, and interferon should be used only with great caution in patients with pre-existing autoimmune diseases. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?